Nonmyeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders

Blood

Volumn 100, Issue 9, 2002, Pages 3121-3127

  Pérez Simón, José A ^a   Kottaridis, Panagiotis D ^a   Martino, Rodrigo ^a   Craddock, Charles ^b   Caballero, Dolores ^b   Chopra, Raj ^c   García Conde, Javier ^c   Milligan, Don W ^d   Schey, Stephen ^d   Urbano Ispizua, Alvaro ^e   Parker, Anne ^e   Leon, Angel ^f   Yong, Kwee ^f   Sureda, Ana ^g   Hunter, Ann ^g   Sierra, Jordi ^h   Goldstone, Anthony H ^h   Linch, David C ⁱ   San Miguel, Jesus F ⁱ   Mackinnon, Stephen ^j  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c Hospital Sant Pau I Santa Creu   (Spain)

^d Heartland Hospital   (United Kingdom)

^e Hospital Clinico de Valencia   (Spain)

^f CHRISTIE HOSPITAL   (United Kingdom)

^g HOSPITAL CLÍNIC   (Spain)

^h GUY S HOSPITAL   (United Kingdom)

ⁱ HOSPITAL DE JEREZ   (Spain)

^j LEICESTER ROYAL INFIRMARY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; METHOTREXATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFUSION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SPAIN; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; UNITED KINGDOM; VIRUS REACTIVATION;

EID: 0036838640     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0701     Document Type: Article

References (50)

1. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft versus host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994;330:100-106.
2. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients relapsed with malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
3. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041-2050.
4. Lockhorst HM, Schattenberg A, Cornelissen JJ, Thomas LLM, Verdonk LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood. 1997;90:4206-4211.
5. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft versus myeloma effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 1995;86:2041-2050.
6. Pérez-Simón JA, Caballero D, Lopez-Pérez R, et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia. 2002;16:1423-1431.
7. Bortin MM, Horowitz MM, Gale RP, et al. Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. JAMA. 1992;268:607-612.
8. Armitage JO. Bone marrow transplantation. N Engl J Med. 1994;330:827-838.
9. Klingemann HG, Storb R, Fefer A, et al. Bone marrow transplantation in patients aged 45 years and older. Blood. 1986;65:770-776.
10. Ringden O, Horwitz MH, Gale RP, et al. Outcome after allogeneic bone marrow transplantation for leukemia in older patients. JAMA. 1993;270:57-60.
11. Blumme KG, Forman SJ, Nademanee AP, et al. Bone marrow transplantation for hematologic malignancies in patients aged 30 years or older. J Clin Oncol. 1986;4:1489-1492.
12. Slavin S, Weiss L, Morecki S, Weigensberg M. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation. Cancer Immunother. 1981;11:155-158.
13. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation, Blood. 1997;89:3048-3054.
14. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
15. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft versus leukemia without myeloablative therapy. Blood. 1997;89:4531-4536.
16. McSweeney P, Niederwieser D, Shizuru J, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high dose cytotoxic therapy with graft versus tumor effect. Blood. 2001;97:3390-3400.
17. Giralt S, Thall P, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631-637.
18. Khouri IF, Keating M, Körbling M, et al. Transplant-lite induction of graft-versus-malignancy using fludarabine based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824.
19. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood. 1999;94:3234-3241.
20. Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood. 2001;97:2574-2579.
21. Kottaridis PD, Milligan D, Chopra R, et al. In vivo alemtuzumab prevents graft-versus-host disease following non myeloablative stem cell transplantation. Blood. 2000;96:2419-2425.
22. Weiden PL, Sullivan KM, Floumoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft versus host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529-1533.
23. Horowitz MM, Gale RP, Sondel PM, et al. Graft versus leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.
24. Childs RW, Chernoff A, Contentin N, et al. Regression of metastatic renal cell carcinoma after nonmyeloablative allogeneic peripheral blood stem cell transplantation. N Engl J Med. 2000;343:750-758.
25. Bertz H, Burger JA, Kunzmann R, Mertelsmann R, Finke J. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): Evidence for a graft versus myeloma effect. Leukemia. 1997;11:281-283.
26. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine based low intensity conditioning regimen for malignant lymphomas. Bone Marrow Transplant. 2000;25:1021-1028.
27. Roux E, Helg C, Chapuis B. Mixed chimerism after bone marrow transplantation and the risk of relapse. Blood. 1994;83:4385-4386.
28. Mackinnon S, Barnett L, Bourhis JH, Black P, Heller G, O'Reilly RJ. Myeloid and lymphoid chimaerism after T-cell depleted bone marrow transplantation: Evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood. 1992;80:3235-3241.
29. Martino R, Caballero D, Canals C, et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: Results of a prospective multicenter study. Br J Hematol. 2001;115:653-659.
30. Przepiorka D, Weisdorf D, Martin P, et al. Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-830.
31. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57:267-276.
32. Boeckh M, Bowden RA, Gooley T, Myerson D, Corey L. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood. 1999;93:1781-1787.
33. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood. 1996;88:4063-4071.
34. Mackinnon S, Papadopoulos EP, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leucocytes for relapse of chronic myeloic leukemia following bone marrow transplantation: Separation of graft versus leukemia responses from graft versus host disease. Blood. 1995;86:1261-1268.
35. Naparstek E, Or R, Nagler A, et al. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and posttransplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol. 1995;89:506-515.
36. Van Besien K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998;92:1832-1836.
37. Rondon G, Giralt S, Huh Y, et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant. 1996;18:669-672.
38. Khouri IF, Przepiorka D, van Besien K, et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: Timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol. 1997;97:466-473.
39. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: Proof of principle. Blood. 1996;87:1196-1198.
40. Mackinnon S. Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation? Br J Haematol. 2000;110:12-17.
41. Apperley JF, Mauro FR, Goldman JM, et al. Bone marrow transplantation for chronic myeloid leukemia in first chronic phase: Importance of a graft versus leukemia effect. Br J Haematol. 1998;69:239-245.
42. Hale G, Cobbold S, Novitzky N, et al. on behalf of CAMPATH users. CAMPATH-1 antibodies in stem cell transplantation. Cytotherapy. 2001;3:145-164.
43. Martino R, Caballero D, Canals C, et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral Blood stem cell transplantation. Bone Marrow Transplant. 2001;28:341-347.
44. Camargo LF, Uip DE, Simpson AA, et al. Comparison between antigenemia and a quantitative-competitive polymerase chain reaction for the diagnosis of cytomegalovirus infection after heart transplantation. Transplantation. 2001;71:412-417.
45. Guiver M, Fox AJ, Mutton K, Mogulkoc N, Egan J. Evaluation of CMV viral load using TaqMan CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplantation. Transplantation 2001;71:1609-1615.
46. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33:139-144.
47. Martin PJ, Influence of alloreactive T cells on initial hematopoietic reconstitution after marrow transplantation. Exp Hematol. 1995;23:174-179.
48. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood. 1999;94:2208-2216.
49. Gross TG, Steinbuch M, DeFor T, et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: Risk factors, treatment and outcome. Bone Marrow Transplant. 1999;23:251-258.
50. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of CAMPATH-1H in delaying immune reconstitution. Blood. 2002;99:4357-4363.